Patents by Inventor Paul J. Yazaki

Paul J. Yazaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD33 antibody-guided imaging and treatment of acute myeloid leukemia
    Patent number: 11666672
    Abstract: Disclosed is a non-invasive PET-CT imaging method for detecting acute myeloid leukemia (AML) or extramedullary disease (EMD) in a subject using a radioactive isotope-labeled anti-CD33 antibody. Also disclosed is a PET-CT imaged-guided method for treating AML or EMD.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: June 6, 2023
    Assignee: CITY OF HOPE
    Inventors: Susanta Kumar Hui, Paul J. Yazaki, Srideshikan Sargur Madabushi
  • DUAL BISPECIFIC ANTIBODY COMPOUNDS AND USES THEREOF
    Publication number: 20220280568
    Abstract: Provided herein, inter alia, are methods of using bispecific antibody compounds which may bind immune cells and are, inter alia, useful for treating cancers. Anti-tumor antigen antibodies are connected to anti-immune antibodies through their hinge regions using, for example, click chemistry to form dual-specific, bivalent BiTES with high in vivo tumor targeting ability and tumor cytotoxicity.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 8, 2022
    Inventors: John E. SHIVELY, Maciej KUJAWSKI, Lin LI, Paul J. YAZAKI
  • ANTI-CD33 ANTIBODY-GUIDED IMAGING AND TREATMENT OF ACUTE MYELOID LEUKEMIA
    Publication number: 20200230265
    Abstract: Disclosed is a non-invasive PET-CT imaging method for detecting acute myeloid leukemia (AML) or extramedullary disease (EMD) in a subject using a radioactive isotope-labeled anti-CD33 antibody. Also disclosed is a PET-CT imaged-guided method for treating AML or EMD.
    Type: Application
    Filed: November 21, 2019
    Publication date: July 23, 2020
    Inventors: Susanta Kumar HUI, Paul J. YAZAKI, Srideshikan Sargur MADABUSHI
  • Humanized anti-CEA T84.66 antibody and uses thereof
    Patent number: 7776330
    Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: August 17, 2010
    Assignee: City of Hope
    Inventors: Paul J. Yazaki, Mark A. Sherman, John E. Shively, Andrew A. Raubitschek, Anna M. Wu
  • Humanized anti-CEA T84.66 antibody and uses thereof
    Patent number: 7273608
    Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: September 25, 2007
    Assignee: City of Hope
    Inventors: Paul J. Yazaki, Mark A. Sherman, John E. Shively, Andrew A. Raubitschek, Anna M. Wu